These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 26871712)
1. Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles. Daniels-Treffandier H; de Nie K; Marsay L; Dold C; Sadarangani M; Reyes-Sandoval A; Langford PR; Wyllie D; Hill F; Pollard AJ; Rollier CS PLoS One; 2016; 11(2):e0148840. PubMed ID: 26871712 [TBL] [Abstract][Full Text] [Related]
2. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine. Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM mBio; 2019 Jun; 10(3):. PubMed ID: 31213564 [TBL] [Abstract][Full Text] [Related]
3. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. Beernink PT; Shaughnessy J; Pajon R; Braga EM; Ram S; Granoff DM PLoS Pathog; 2012; 8(5):e1002688. PubMed ID: 22589720 [TBL] [Abstract][Full Text] [Related]
4. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity. Giuntini S; Pajon R; Ram S; Granoff DM Infect Immun; 2015 Apr; 83(4):1536-45. PubMed ID: 25644002 [TBL] [Abstract][Full Text] [Related]
5. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification. Zhang L; Wen Z; Lin J; Xu H; Herbert P; Wang XM; Mehl JT; Ahl PL; Dieter L; Russell R; Kosinski MJ; Przysiecki CT Vaccine; 2016 Jul; 34(35):4250-4256. PubMed ID: 27269057 [TBL] [Abstract][Full Text] [Related]
6. Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice. Lujan E; Pajon R; Granoff DM Infect Immun; 2016 Feb; 84(2):452-8. PubMed ID: 26597984 [TBL] [Abstract][Full Text] [Related]
7. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. Costa I; Pajon R; Granoff DM mBio; 2014 Aug; 5(5):e01625-14. PubMed ID: 25161192 [TBL] [Abstract][Full Text] [Related]
8. Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? Granoff DM; Ram S; Beernink PT Clin Vaccine Immunol; 2013 Aug; 20(8):1099-107. PubMed ID: 23740919 [TBL] [Abstract][Full Text] [Related]
9. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. Lewis LA; Ngampasutadol J; Wallace R; Reid JE; Vogel U; Ram S PLoS Pathog; 2010 Jul; 6(7):e1001027. PubMed ID: 20686663 [TBL] [Abstract][Full Text] [Related]
10. A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies. Beernink PT; Ispasanie E; Lewis LA; Ram S; Moe GR; Granoff DM J Infect Dis; 2019 Mar; 219(7):1130-1137. PubMed ID: 30346576 [TBL] [Abstract][Full Text] [Related]
11. Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H. Rossi R; Konar M; Beernink PT Infect Immun; 2016 Jun; 84(6):1735-1742. PubMed ID: 27021245 [TBL] [Abstract][Full Text] [Related]
12. 4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp. Veggi D; Bianchi F; Santini L; Lo Surdo P; Chesterman CC; Pansegrau W; Bechi N; Huang Y; Masignani V; Pizza M; Rappuoli R; Bottomley MJ; Cozzi R; Maione D PLoS Pathog; 2020 Oct; 16(10):e1008882. PubMed ID: 33007046 [TBL] [Abstract][Full Text] [Related]
13. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. Beernink PT; Shaughnessy J; Braga EM; Liu Q; Rice PA; Ram S; Granoff DM J Immunol; 2011 Mar; 186(6):3606-14. PubMed ID: 21325619 [TBL] [Abstract][Full Text] [Related]
14. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. Johnson S; Tan L; van der Veen S; Caesar J; Goicoechea De Jorge E; Harding RJ; Bai X; Exley RM; Ward PN; Ruivo N; Trivedi K; Cumber E; Jones R; Newham L; Staunton D; Ufret-Vincenty R; Borrow R; Pickering MC; Lea SM; Tang CM PLoS Pathog; 2012; 8(10):e1002981. PubMed ID: 23133374 [TBL] [Abstract][Full Text] [Related]
15. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968 [TBL] [Abstract][Full Text] [Related]